Clenbuterol (hydrochloride)
(Synonyms: 盐酸克仑特罗,NAB 365,Ventipulmin) 目录号 : GC12778
A β2-AR agonist
Cas No.:21898-19-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Clenbuterol is a sympathomimetic β2-adrenoceptor agonist.
β2-adrenoceptor agonists, mainly long-acting β2-adrenoceptor agonists, are an important pharmacological approach to induce bronchodilation in patients with chronic obstructive pulmonary disease.
In vitro: A hormone dependent human breast cancer cell line was treated with different concentrations of clenbuterol. It was found that clenbuterol could stimulate cell proliferation at low concentrations, but the effect was less marked and significant compared with oestradiol. Probably clenbuterol elicited cell proliferation via a different mechanism, because it did not affect the cellular oestrogen receptor concentration [1].
In vivo: Clenbuterol was administered to Fischer-344 rats, at a dose of 1.5 mg/kg/24 h for 3 weeks. The weights of five hindlimb muscles and carcass protein and fat content were determined. Results showed that clenbuterol treatment could increase the weight of skeletal muscles of all animals. Similarly, clenbuterol increased carcass protein conten, leading to the reduced carcass fat content [2].
Clinical trial: Clenbuterol was compared with terbutaline during a 5-week single-blind crossover study in patients with chronic airways obstruction. Both clenbuterol and terbutaline could significantly improve baseline FEV1 and the bronchodilator effects were similar, suggesting that clenbuterol was a good alternative drug for treatment of chronic airways obstruction [3].
References:
[1] Re G, Badino P, Girardi C, Di Carlo F. Effects of a beta 2-agonist (clenbuterol) on cultured human (CG-5) breast cancer cells. Pharmacol Res. 1992 Dec;26(4):377-84.
[2] Carter WJ, Dang AQ, Faas FH, Lynch ME. Effects of clenbuterol on skeletal muscle mass, body composition, and recovery from surgical stress in senescent rats. Metabolism. 1991 Aug;40(8):855-60.
[3] Brusasco V, Crimi E, Mangini S, Vibelli C. A clinical trial of oral clenbuterol (NAB 365) in chronic airways obstruction. Curr Med Res Opin. 1980;6(7):449-55.
| Cas No. | 21898-19-1 | SDF | |
| 别名 | 盐酸克仑特罗,NAB 365,Ventipulmin | ||
| 化学名 | 4-amino-3,5-dichloro-α-[[(1,1-dimethylethyl)amino]methyl]-benzenemethanol, monohydrochloride | ||
| Canonical SMILES | ClC1=CC(C(O)CNC(C)(C)C)=CC(Cl)=C1N.Cl | ||
| 分子式 | C12H18Cl2N2O • HCl | 分子量 | 313.7 |
| 溶解度 | ≥ 13.15mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1878 mL | 15.9388 mL | 31.8776 mL |
| 5 mM | 0.6376 mL | 3.1878 mL | 6.3755 mL |
| 10 mM | 0.3188 mL | 1.5939 mL | 3.1878 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet